Infectious disease can be interpreted as a disease caused by infectious agents (bacteria, viruses, fungi, and parasites) or toxic products that are transmitted from infected people, animals, and reservoirs, either directly or indirectly. The main therapy for infectious diseases, especially bacterial infections, is to use antibiotics. However, the massive use of antibiotics and the tendency to frequently abuse them have led to the development of antibiotic resistance in pathogenic bacteria. Therefore, a new solution is needed to overcome the high rate of antibiotic resistance. Bacteria can develop resistance characteristics through two main mechanisms. The first mechanism is by carrying out intrinsic genetic mutations that support the achievement of resistance traits, while the second mechanism is by the acquisition of mobile genetic elements. Plasmid-mediated resistance is one of the important mechanisms in increasing antibiotic resistance. Antiplasmid agents are compounds that are capable of inhibiting plasmid replication, which in turn results in the elimination of bacterial plasmids. Various compounds have the potential to be used as antiplasmid agents, for instance, DNA intercalating agents, psychotropic drugs, detergents, biocides, and various compounds derived from herbs. One of the biggest challenges of antiplasmid therapy is the fact that most antiplasmid agents are mutagenic, carcinogenic, and teratogenic when they attack human cells. Therefore, the use of engineered bacteriophage has the potential to be used as a delivery medium for antiplasmid agents to go directly to pathogenic bacteria without damaging the body cells.